TUESDAY, JUNE 18 | beginning at 4:20pm
How are life science companies improving R&D productivity and maintaining a fast pace of drug discovery and development? How are they decreasing the rate of translational failures? The World Pharma Week plenary session will tackle these and other
questions by highlighting two stories from two worlds, a top pharma company and a small biotech. The common denominator is the goal of bringing novel therapies safely and effectively to patients and their physicians.
4:20 Welcome Remarks
Marina Filshtinsky, MD, Executive Director, Conferences, Cambridge Healthtech Institute
4:30 TURNING SCIENCE INTO MEDICINE: The Science behind the 5R Framework
Stephen Fawell, PhD, Vice President, Head Oncology Discovery, AstraZeneca
Morgan P, Brown DG, Lennard S, Anderton MJ, Barrett JC, Eriksson U, Fidock M, Hamrén B, Johnson A, March RE, Matcham J, Mettetal J, Nicholls DJ, Platz S, Rees S, Snowden MA, Pangalos MN. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nature Reviews Drug Discovery (2018) 17, 167–181.
Cook D, Brown D; Alexander R, March R, Morgan P, Satterthwaite G and Pangalos MN. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nature Reviews Drug Discovery (2014) 13, 419-431.
Improving R&D productivity is critical to the success of drug discovery, with failure rates from pre-clinical development to launch often in excess of 90 percent. In AstraZeneca, we conducted an in-depth review of our R&D activities to help
us identify ‘success factors’ that could improve the probability of success for any given drug discovery program. As a result, we launched the ‘5R framework’: right target, right tissue, right safety, right patient, and
right commercial, focused on the quality of our programs rather than the quantity of programs. In the five years since inception of this 5R framework our success rates have increased almost five-fold to 19% from pre-clinical investigation to completion
of Phase III clinical trials.
4:55 MINING FOR TOMORROW’S CURES: A Nex-Gen Model of Drug Development
Jennifer Michaelson, PhD, Vice President, Preclinical Research & Early Development, Cullinan Oncology
Drug development in oncology and immuno-oncology is accelerating at a record pace. The multitude of drug targeting modalities and mechanisms being pursued within big pharma and biotech is astounding. Cullinan Oncology has a unique approach to leverage
the array of cutting-edge opportunities and broad range of scientific approaches within the fast moving oncology drug development space. A hybrid operating structure enables Cullinan to develop a diversified oncology portfolio of single asset
opportunities across a range of mechanisms and modalities within oncology and immune-oncology. The model entails a balance of externally and internally derived programs, a cost-efficient management structure, and an outsourced model to drive speed,
nimbleness, risk diversification and efficiency. Case studies exemplifying the efficiency in getting to key go/no go decisions will be presented. The ultimate goal is to develop high value oncology therapeutics that have the potential to significantly
improve upon standard of care for patients.
5:25 Meet the Plenary Keynotes! Join us at the Solutions Theater in the Commonwealth Hall to meet the Plenary Keynotes and ask additional questions.
WEDNESDAY, JUNE 19 | beginning at 12:50pm
12:50 pm Organizer Welcome Remarks
12:55 Controlling Prescription Drug Pricing: Where is it Headed?
Ed Silverman, Pharmalot Columnist, Senior Writer, STAT
The Trump administration, Congressional Democrats and lawmakers in a growing number of states are pushing various proposals to lower drugs costs. The ideas include eliminating rebates for federal health programs; tying prices for some Medicare drugs
to an international pricing index; treating drug makers as utilities and importing medicines from Canada. But which, if any, can gain traction?
1:15 Introduction for the Plenary Panel
Ashoka Rajendra, Head, Product, Molecular Biology and Inventory, Benchling
1:30 PLENARY PANEL DISCUSSION: Data Driven Drug Discovery and Development: Digital, AI and ML to Re-Shape R&D
Peter Henstock, PhD, AI & Machine Learning Lead, Pfizer
Litao Zhang, PhD, Vice President, Leads Discovery and Optimization, Bristol-Myers
Peter Bergethon, Vice President, Quantitative Medicine & Clinical Technologies, Biogen
Jason Laramie, PhD, Vice President, Global Head, Translational Medicine Data Science, Novartis Institutes for BioMedical Research (NIBR)
Jamileh Jemison, MS, MD, Head of Clinical Development, Healthmode
This panel will ask leaders focused on drug discovery and development how they view AI/ML/Digital as an opportunity over the next 1-5 years to improve their business including:
- In what parts of the business do they see the most opportunities and needs now?
- How does these technologies fit within their overall strategy?
- What is the right balance of partnering externally versus developing an internal Digital/AI team?
- What were the challenges in kickstarting the first AI/Digital projects?
2:25 Meet the Plenary Keynotes! Join us at the Solutions Theater in the Commonwealth Hall to meet the Plenary Keynotes and ask additional questions.
Join us for an IO focused Keynote Panel on Partnering Ecosystem as part of the IO Pharma Congress.
TUESDAY, JUNE 18 | beginning at 3:10pm
IO PLENARY SESSION: PARTNERING ECOSYSTEM
PANEL DISCUSSION: Partnering, Preclinical Strategies and Tools, IO Clinical Trials; Capital Invested in IO Relative to Other Oncology Areas
Leigh Zawel, PhD, CSO, Cullinan Oncology; Executive Partner, MPM Capital
Michael Woo, MBA, Head, Search & Evaluation, Immuno-Oncology, Business Development & Licensing, Novartis Institutes for BioMedical Research, Inc.
Sybil Williams, PhD, Director, Biology Oncology Discovery, Merck
Paul Young, PhD, Executive Director, Business Development & Licensing, Merck
Stacey J. Adam, PhD, Director, Cancer Research Partnerships, Foundation for the National Institutes of Health
- Has the IO bubble popped? Why have no other IO drugs emerged with PD1/PDL1-like efficacy?
- What combination strategies are being explored to convert poorly PD1 responsive tumors to more responsive ones?
- Are there new IO monotherapies or combos that appear promising?
- Is patient stratification practical with IO therapies?
- What partnering strategies are most effective?
- What is a recent deal your firm signed that you’re excited about?